Navigation Links
FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy
Date:9/14/2010

EAST BRUNSWICK, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.  Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

"KRYSTEXXA is the first-ever and only treatment approved by the FDA for adult patients who suffer with chronic gout that is refractory to conventional therapy," said Paul Hamelin R.Ph., President of Savient Pharmaceuticals.  "The clinical data have demonstrated that many patients treated with KRYSTEXXA 8 mg administered every two weeks can experience within six months of treatment significant positive clinical improvement reversing the course of this severe, crippling and debilitating disease. A statistically significant proportion of patients in our pivotal clinical trials achieved a lowering of their serum uric acid level to a mean of 0.7 mg/dL and achieved a complete response for the resolution of tophi within the first six months of therapy. We believe that the approval of KRYSTEXXA is a significant step towards realizing our mission of transforming the lives of the patients in the U.S. suffering with chronic gout refractory to conventional therapy, as many of them finally have a treatment that gives them hope of reversing this severely debilitating disease."

Savient expects KRYSTEXXA to be available by prescription in the U.S. later this year a
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. European Union Approves Maize with Herculex® I/Herculex® RW and Herculex® RW/ Herculex® I/Roundup Ready® Corn 2 Trait Stacks for Import, Food, Feed & Processing
2. FDA Approves First-of-Its-Kind HIV Test Which Can Detect HIV Days Earlier Than Current U.S. Tests
3. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
4. FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
5. European Union Approves Corn Stack with Herculex RW and Roundup Ready 2 Traits for Food, Feed, Import and Processing
6. EU Committee Approves New Food Applications for Marteks lifesDHA(TM)
7. EU Committee Approves New Food Applications for Martek's life'sDHA™
8. Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler
9. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
10. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
11. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 In keeping with the holiday ... bevy of last-minute Thanksgiving savings. The company is offering ... all product lines this holiday weekend as well as ... Friday, and Cyber Monday are right around the corner, ... both loyal customers and those looking to explore their ...
(Date:11/26/2014)... 26, 2014 The ETC (Emerging ... technology innovation centers, announced today that applications for ... December 1st. “Do you have a big idea?,” ... want to know about it. AccelerateBaltimore helps you ... product in just 13 weeks.” Interested game ...
(Date:11/26/2014)... 25, 2014 Continuing its award-winning streak, ... three prestigious MarCom Awards for outstanding creative achievement by ... Platinum MarCom Award, the organization’s top honor, in the ... Louis held in April of this year. The event ... attendees. Additionally, Nerium was awarded a Gold MarCom Award ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 CURE™ ... recognition reception on December 5, 2014, in San Francisco ... The MPN Heroes event will honor clinicians, caregivers, and ... of myeloproliferative neoplasms (MPNs). , Special guest speaker ... his family's cancer journey at the reception. Over ...
Breaking Biology Technology:DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... NEW YORK, June 23 Medicsight PLC, a,subsidiary of ... an industry,leader in the development of Computer-Aided Detection (CAD) ... and Lucan Toh,(Director of Business Development) will be presenting ... 24th June., The conference will be held from ...
... Cystinosis Foundation Ireland to Host Event June 27-28, ... Corp. ("Raptor" or the "Company") (OTC Bulletin Board:,RPTP), ... clinical,division, will present at the Cystinosis Foundation Ireland,s ... 2008 at the,Hilton Hotel, Dublin City, Charlemont Place, ...
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer ... services, today announced Health Canada -- Medical,Device ... of the ATS,Open Pivot(R) AP360(TM) Mechanical Heart ... The ATS AP360 heart valve maximizes ...
Cached Biology Technology:Medicsight to Present at Piper Jaffray Annual Europe Conference 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 3Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 4Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 5ATS Medical Announces Canadian Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve 2
(Date:11/5/2014)... biology in the UTSA College of Sciences, is ... to receive a two-year $300,00 National Science Foundation ... The funding supports President Obama,s BRAIN Initiative, a ... technology that will demystify complex brain processes. ... are broken into the interactions of multiple components, ...
(Date:11/5/2014)... diversity in their ability to identify scents and odors. ... their perceptual evaluation of odors, with women outperforming men ... Sex differences in olfactory detection may play a role ... one,s perception of smell, which is naturally linked to ... been suggested to be cognitive or emotional, rather than ...
(Date:11/4/2014)... the right amount of death at the right time ... to new research that could help in understanding animal ... , In a paper in the journal Trends ... and European colleagues conclude that the kind of positive ... of individuals, or mortality, depends on the size and ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2
... gene that contributes to insulin resistance appears to prevent ... researchers say. Cardiovascular disease is the biggest health ... trying to understand why have knocked out protein tyrosine ... get diabetes. "Even before you have really bad ...
... to move swiftly to pass economic recovery legislation ... including the National Science Foundation (NSF), the Department ... and Space Administration (NASA), and National Institute of ... of the American Recovery and Reinvestment Act included ...
... National Institute of Standards and Technology (NIST) has ... be an important quality assurance tool for measuring ... in dietary supplements. The new Standard Reference Material ... collaboration with the Office of Dietary Supplements (ODS) ...
Cached Biology News:Decreasing insulin resistance prevents obesity-related cardiovascular damage 2Decreasing insulin resistance prevents obesity-related cardiovascular damage 3Basic research critical to America's economic recovery 2New reference material can improve testing of multivitamin tablets 2